Trial Profile
A retrospective study to evaluate gefitinib as a first line treatment in non-small cell lung cancer patients with activating EGFR mutations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Mar 2016
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Mar 2016 New trial record